Panelists discuss how community practices establish protocols and processes for ongoing monitoring and management of potential long-term complications or adverse events from bispecific therapy.
What protocols and processes do you have in place at the community practice to continue monitoring and managing potential long-term complications or adverse events associated with bispecific therapy?